QL-325 by QLSF Biotherapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
QL-325 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData's report assesses how QL-325's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.QL-325 overviewQL-325 is under development for the treatment of acute myeloid leukemia (AML). It is a bi-specific monoclonal antibody which acts by targeting an undisclosed tumor-associated antigen and CD3.For a complete picture of QL-325's drug-specific PTSR and LoA scores, buy the report here.
QL-325 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
What's Your Reaction?
